Sector News

J&J adds 200 jobs with new biopharma plant at site in Ireland

October 8, 2019
Life sciences

Johnson & Johnson’s Janssen has had biopharma operations in Ringaskiddy, Co. Cork for nearly 15 years. Now it has a new $350 million facility and added 200 jobs.

The official opening, which was announced by IDA Ireland, boosted the site’s size by 19,100 square meters (205,590 square feet).

“Our Ringaskiddy facility is an important part of our global manufacturing network and expanding our capabilities here will allow us to pursue innovative solutions …” Kathy Wengel, J&J’s chief global supply chain officer, said in a statement.

The company started on the €300 million project in 2017. The additions included expansion of an existing warehouse, laboratory and administration buildings, and expansion of the wastewater treatment plant to accommodate increased volumes.

At the time the company said the new plant would bolster capacity of APIs for drugs that treat “multiple myeloma, rheumatoid arthritis and Crohn’s disease.” While it didn’t specifically identify the products to be made there, J&J sells blockbuster Remicade for rheumatoid arthritis and Crohn’s disease, as well as Simponi for treating rheumatoid arthritis and Stelara for treating Crohn’s disease.

According to a new forecast from GlobalData, Stelara is expected to be the ninth-best selling drug globally in 2025 with $7.5 billion in sales.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

November 19, 2022

Sequana announces results from study of direct sodium removal

Life sciences

Sequana, a company focusing on liver disease, heart failure and cancer has announced positive top-line results from SAHARA – the phase 2a study using its first-generation direct sodium removal (DSR) product, DSR 1.0. Data from ten evaluable diuretic-resistant heart failure patients confirmed long-lasting clinical benefits.

November 19, 2022

Bristol Myers Squibb opens 125-acre biologics campus in Dublin

Life sciences

Bristol Myers Squibb has officially opened its Cruiserath Biologics site in Dublin. The site, which represents a $1bn investment – was officially opened by the company’s chief executive officer, Giovanni Caforio, who arrived from New York, and site general manager Pádraig Keane.

November 19, 2022

Pharma must stay the course on Twitter as docs are not abandoning the platform yet: Report

Life sciences

Like it or loathe it, and whatever its new direction, Twitter is still a powerful platform for doctors, and pharma should not abandon the troubled social media site yet, according to a new report from healthcare consultants at ZoomRx.